Product Description
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23) (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25810327/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Indonesia
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Communicable Diseases|Pneumococcal Infections|Pneumonia, Pneumococcal
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06617715 |
PRO-PCV-3001 | P3 |
Recruiting |
Pneumococcal Infections|Communicable Diseases |
2025-10-12 |
29% |
2025-02-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments |
NCT03384589 |
H17-02645 | P3 |
Completed |
Pneumococcal Infections|Pneumonia, Pneumococcal |
2023-03-31 |
2024-03-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06183216 |
PRO-PCV-1002 | P1 |
Active, not recruiting |
Communicable Diseases|Pneumococcal Infections |
2025-02-15 |
50% |
2025-04-18 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05092386 |
PRO-PCV-1001 | P1 |
Completed |
Pneumococcal Infections |
2024-05-26 |
2024-12-21 |
Primary Endpoints |
|
NCT05934890 |
PCV13-004 | P3 |
Active, not recruiting |
Pneumococcal Infections |
2025-03-01 |
24% |
2024-07-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |